CDA | Evidence Driven
CDA | Evidence Driven

Immune Checkpoint Inhibitors for Non–Small Cell Lung Cancer With Genomic Aberrations

Details

Files
Project Status:
Active
Project Line:
Health Technology Review
Project Sub Line:
Systematic Review
Project Number:
RE0050-000
Expected finish date:

Immune checkpoint inhibitors (ICIs) are approved as monotherapy for non–small cell lung cancer (NSCLC). Metastatic NSCLC with mutations or rearrangements (ALK, EGFR, ROS-1, BRAF, MET, RET) are known to respond poorly to ICIs and should be first treated with targeted drugs and chemotherapy. This systematic review will synthesize the evidence on the benefits of ICIs when used as third-line therapy or beyond for mutated NSCLC.

Files

Draft Report View PDF
Proposed Protocol View PDF
Last Updated : June 13, 2024